Search clinical trials for: OROS hydromorphone HCl

Total 3151 results

Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer

Pain | Cancer
Janssen-Cilag International NV

Completed

Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee

Pain | Osteoarthritis, Knee | Osteoarthritis, Hip

United Kingdom, Romania, Slovakia, Czech Republic
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.

Pain

France, Poland, Germany, Slovenia, Sweden, Czech Republic, Norway, Slovakia, Switzerland, Denmark
Alza Corporation, DE, USA

Completed

An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)

Osteoarthritis, Knee | Osteoarthritis, Hip
Alza Corporation, DE, USA

Completed

A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.

Pain | Analgesics, Opioid
Janssen Korea, Ltd., Korea

Completed

Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid

Pain

Korea, Republic of
Alza Corporation, DE, USA

Completed

A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain

Pain | Analgesics | Opioid
Alza Corporation, DE, USA

Completed

A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain

Pain, Postoperative | Analgesia | Orthopedic Procedures
Alza Corporation, DE, USA

Completed

A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis

Osteoarthritis, Knee | Osteoarthritis, Hip
Alza Corporation, DE, USA

Completed

Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain

Pain
Alza Corporation, DE, USA

Completed

Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain

Low Back Pain
Alza Corporation, DE, USA

Completed

An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg

Analgesia
Alza Corporation, DE, USA

Completed

A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain

Low Back Pain
Janssen Korea, Ltd., Korea

Completed

Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients

Cancer Pain

Korea, Republic of
Mallinckrodt

Completed

A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain

Chronic Pain
Janssen Korea, Ltd., Korea

Completed

An Observational Study to Investigate Clinical Usefulness of OROS Hydromorphone in Korean Cancer Patients

Pain
Mallinckrodt

Completed

Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain

Chronic Low Back Pain
Johnson & Johnson Taiwan Ltd

Terminated

A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain

Cancer Pain
Janssen Pharmaceutica

Terminated

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

Pain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain

Pain

China
Shirley Ryan AbilityLab
Mallinckrodt

Completed

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain (Covidien)

Low Back Pain

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Vishal Uppal

Completed

Pre-emptive Opioid Treatment to Prevent Rebound Pain After Arthroscopic Rotator Cuff Repair and/or Acromioplasty Under General Anesthesia and Interscalene Block

Pain | Rotator Cuff Injury

Canada
Mallinckrodt

Terminated

Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients

Chronic Pain

United States
Mayo Clinic

Recruiting

A Study of Intrathecal Hydromorphone for Pediatric Idiopathic Scoliosis Repair

Pain Control

United States
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Mayo Clinic
National Cancer Institute (NCI)

Completed

Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies

Malignant Female Reproductive System Neoplasm

United States
AUVA Traumazentrum Vienna Site UKH Meidling

Completed

Pain Management After Elective Shoulder Surgery

Postoperative Pain

Austria
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults

Healthy Volunteers

United States
Alza Corporation, DE, USA

Completed

An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg

Analgesia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants

Healthy Volunteers

Taiwan
Brigham and Women's Hospital

Terminated

Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study

Pain | Healthy | Pregnancy

United States
Thomas Jefferson University

Completed

Intrathecal Hydromorphone for Cesarean Section

Pain

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
University of Virginia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

Type 1 Diabetes

United States
Massachusetts General Hospital

Withdrawn

Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging

ADHD

United States
University of California, San Francisco
National Cancer Institute (NCI); Celgene Corporation; Westat; African Esophageal...

Recruiting

Treatment Outcomes of Esophageal Cancer

Esophageal Cancer

Tanzania, Kenya, Malawi
Rabin Medical Center
Medtronic; GIF

Completed

An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Glycemic Control Using Hybrid-closed Loop vs. Advanced Hybrid Closed-loop in Young Subjects With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany, Israel
University of Miami

Completed

CROS Application in CI (CROS)

Hearing Loss

United States
Janssen Korea, Ltd., Korea

Completed

An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Rabin Medical Center

Completed

Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2

Type 1 Diabetes

Israel
Advanced Bionics AG

Completed

Benefits of a Contralateral Routing of Signals (CROS) System in Unilateral CI-recipients

Cochlear Implants

France
Alza Corporation, DE, USA

Completed

A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder
Alza Corporation, DE, USA

Completed

A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children

Attention Deficit Hyperactivity Disorder
University of British Columbia
Canadian Institutes of Health Research (CIHR); Providence Healthcare; Innerchange...

Completed

Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) (SALOME)

Heroin Dependence | Opioid Dependence

Canada
Alza Corporation, DE, USA

Completed

An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

3

Subscribe